
The FDA approved adrabetadex for infantile-onset NPC based on a 55% lower risk of death vs external controls, with a boxed warning for hearing loss.
Some recent studies show the significant effects of Kawasaki disease on coronary arteries. Researchers all agree on the urgent need for early diagnosis and improved treatment therapies.






